Provided by Tiger Fintech (Singapore) Pte. Ltd.

Keros Therapeutics, Inc.

14.56
+0.12000.83%
Volume:249.76K
Turnover:3.66M
Market Cap:591.36M
PE:133.63
High:14.83
Open:14.44
Low:14.44
Close:14.44
Loading ...

Keros Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
07 May

Keros Therapeutics Q1 EPS $3.62, Sales $211.25M

Benzinga
·
07 May

Keros Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
02 May

Implied Volatility Surging for Keros Therapeutics Stock Options

Zacks
·
02 May

Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS) and Illumina (ILMN)

TIPRANKS
·
11 Apr

BUZZ-U.S. STOCKS ON THE MOVE-AppLovin, Ligand Pharma, Dexcom

Reuters
·
11 Apr

Keros Therapeutics Shares up 16% After Co Adopts 'Poison Pill' Plan

THOMSON REUTERS
·
10 Apr

Sector Update: Health Care

MT Newswires Live
·
10 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Ford Motor, General Motors, AES

Reuters
·
10 Apr

Keros Therapeutics Board Initiates Review of Strategic Alternatives

MT Newswires Live
·
10 Apr

Keros Therapeutics Shares Rise Premarket as Company Mulls Sale

Dow Jones
·
10 Apr

Keros Therapeutics Shares up 17.7% Premarket After Co Adopts 'Poison Pill' Plan

THOMSON REUTERS
·
10 Apr

Keros Therapeutics adopts 'poison pill' plan

Reuters
·
10 Apr

Keros Therapeutics Inc - Adopted Limited-Duration Stockholder Rights Plan

THOMSON REUTERS
·
10 Apr

Truist Cuts Price Target on Keros Therapeutics to $25 From $43, Keeps Buy Rating

MT Newswires Live
·
09 Apr

Keros Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
01 Apr

Scotiabank Remains a Buy on Keros Therapeutics (KROS)

TIPRANKS
·
01 Apr

Keros Therapeutics reports results from Phase 1 clinical trial of KER-065

TIPRANKS
·
31 Mar

BRIEF-Keros Therapeutics Announces Initial Topline Results From Phase 1 Clinical Trial Of KER-065 In Healthy Volunteers

Reuters
·
31 Mar

Keros Therapeutics Announces Initial Topline Results From Phase 1 Clinical Trial of Ker-065 in Healthy Volunteers

THOMSON REUTERS
·
31 Mar